Skip to main content
Premium Trial:

Request an Annual Quote

BD s Q1 Revenues Up 9 Percent, Led by Biosciences, Medical Segment

NEW YORK, Jan. 27 (GenomeWeb News) - Led by double-digit revenue growth in its biosciences and medical segments, Becton Dickinson this week reported $1.3 billion in the first quarter, up 9 percent over $1.2 billion in revenues for the year-ago period.

 

The company's biosciences segment had revenues of $181 million, up 15 percent over the year-ago period's $157 million. The rise in revenues was attributed primarily to sales of the company's FacsCanto analyzer, and the FacsAria cell sorter, and sales of flow cytometry reagents to the clinical and research markets.

 

BD Medical had sales of $694 million, up 11 percent over the year-ago period's $627 million in revenue, while BD Diagnostics had sales of $414 million, up 3 percent over the previous period's $401 million in sales.

 

R&D expenditures were up 6.5 percent to $62 million for the period, compared to $58 million last year.

 

BD's operating income for the quarter was $250 million, up 48 percent over $168 million in Q1 FY '04.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.